

PERSONAL INFORMATION

Mark Ainsworth

WORK EXPERIENCE

November 1986–April 1988

House officer (physician)

Odense University Hospital (Denmark)

Clinical

May 1988–October 1991

Research fellow

Odense University (Denmark)

Research

November 1991–October 1992

Senior house officer

Odense University Hospital (Denmark)

clinical

October 1992–September 1994

Post doc research fellow

University of California, San Diego (United States)

research

October 1994–August 1995

Senior house officer (physician)

Odense University Hospital (Denmark)

clinical

September 1995–October 1998

Specialist registrar (physician)

Copenhagen University Hospital, Herlev and Glostrup (Denmark)

Specialist training in internal medicine

November 1998–February 2004

Senior medical officer/head of section

Danish Medicines Agency (Denmark)

Clinical assessor, management, regulatory activities

Member of Efficacy Working Party, Scientific Advice Working Party and CHMP

March 2004–August 2004

Medical director

Ferring Pharmaceuticals (Denmark)

Clinical research

September 2004–May 2007

Senior house officer (physician)

Copenhagen University Hospital at Herlev (Denmark)

Specialist training in gastroenterology

June 2007–June 2014

Associate specialist, associate professor, head of section

Copenhagen University Hospital at Herlev (Denmark)

Clinical, teaching medical students

July 2014–January 2018 **Head of Departement, Associate professor**
Copenhagen University Hospital at Herlev (Denmark)
Administrative, clinical work, teaching

February 2018–Present **Chief Medical Officer**
Danish Medicines Agency (Denmark)
Regulatory Work, assessment, CHMP

February 2018–Present **Consultant Gastroenterologist**
Odense University Hospital (Denmark)
Clinical

EDUCATION AND TRAINING

September 1980–June 1986 **Medical doctor (cand.med.)**
Odense University (Denmark)

–2001 **Board certified specialist internal medicine**
(Denmark)

–2007 **Board certified specialist in medical gastroenterology and hepatology**
(Denmark)

ADDITIONAL INFORMATION

Expertise Gastroenterology and hepatology
Clinical research/clinical trials
Methodology

Publications Original articles

1. O. Olsen, M. A. Ainsworth, O.B. Schaffalitzky de Muckadell. Effects of oleic acid and oleyl alcohol on cholecystokinin and secretin in plasma and pancreatico-biliary secretion. *Scand. J. Gastroenterol.* 1989;24:52932.
2. M. A. Ainsworth, J. Eriksen, J. Wæver-Rasmussen, O. B. Schaffalitzky de Muckadell : Intestinal permeability of Cr-51-EDTA in patients with Crohn's disease and their healthy relatives. *Scand. J. Gastroenterol.* 1989;24:9938.
3. M. A. Ainsworth, J. Kjeldsen, O.B. Schaffalitzky de Muckadell: Morphine inhibits secretion of bicarbonate from the human duodenal mucosa. Possible role of endogenous opioids in the regulation of human duodenal mucosal bicarbonate secretion. *Scand J Gastroenterol* 1990;25:1066-75.
4. M. A. Ainsworth, J. Kjeldsen, O. Olsen, Christensen P, O.B. Schaffalitzky de Muckadell. Duodenal disappearance rate of acid during inhibition of mucosal bicarbonate secretion. *Digestion* 1990;47:121-29.
5. P. Svendsen, M. A. Ainsworth, A. Carter. Acid base status and cardiovascular function in pigs anaesthetized with alfa-chloralose. *Scand J Lab Anim Sci.* 1990;17:89-95.
6. P. Svendsen, M. A. Ainsworth, H. Glad Sørensen. An animal model for the study of pancreatico-biliary and duodenal secretion. *Scand J Lab Anim Sci* 1991;18:29-34.
7. M. A. Ainsworth, L. Ladegaard, P. Svendsen, P. Cantor, O. Olsen, OB. Schaffalitzky de Muckadell. Pancreatic, hepatic, and duodenal mucosal bicarbonate secretion during infusion of secretin and cholecystokinin. Evidence of the importance of hepatic bicarbonate secretion in the neutralization of acid in the duodenum of anaesthetized pigs. *Scand J Gastroenterology* 1991;26:1035-1041.

8. M. A. Ainsworth, P. Svendsen, L. Ladegard, P. Cantor, O. Olsen, O.B. Schaffalitzky de Muckadell. Relative importance of pancreatic, hepatic and mucosal bicarbonate secretion in duodenal neutralization of acid. *Scand J Gastroenterology* 1992;27:343-349.
9. M. A. Ainsworth, D.L. Hogan, M.A. Koss, J.I. Isenberg. Cigarette smoking inhibits acid-stimulated duodenal mucosal bicarbonate secretion. *Ann Intern Med* 1993;119:882-886.
10. M. A. Ainsworth, C. Fenger, P. Svendsen, O.B. Schaffalitzky de Muckadell. Effect of stimulation of mucosal HCO₃⁻ secretion on acid-induced injury to porcine duodenal mucosa. *Scand J Gastroenterol* 1993;28:1091-1097.
11. H. Glad, P. Svendsen, M. A. Ainsworth, O. Olsen, J.F. Rehfeld, O.B. Schaffalitzky de Muckadell. The effect of Gastrin-Releasing Peptide on porcine pancreaticobiliary bicarbonate secretion is mediated by secretin. *Scand J Gastroenterol* 1994;29:195-202.
12. M. A. Ainsworth, P. Svendsen, H. Glad, N.J. Andersen, O. Olsen, O.B. Schaffalitzky de Muckadell. Duodenal mucosal bicarbonate secretion is accompanied by compensatory changes in pancreatic and biliary HCO₃⁻ secretion. *Scand J Gastroenterol* 1994;29:889-896.
13. M. A. Ainsworth, M.A. Koss, D.L. Hogan, J.I. Isenberg. Higher Proximal Duodenal Mucosal Bicarbonate secretion is independent of Brunner's glands. *Gastroenterology* 1995;109:1160-1166.
14. M. Amelsberg, A. Amelsberg, M. A. Ainsworth, D.L. Hogan, J.I. Isenberg. Cyclic adenosine-3',5'-monophosphate production is greater in rabbit duodenal crypt than villus cells. *Scand J Gastroenterol* 1996;31:233-239.
15. M. A. Ainsworth, M. Amelsberg, D.L. Hogan, J.I. Isenberg. Acid-base transport in isolated rabbit duodenal villus and crypt cells. *Scand J Gastroenterol* 1996;31:1069-77.
16. D.L. Hogan, D.L. Crombie, P.Svendsen, J. I. Isenberg, O.B. Schaffalitzky de Muckadell, M. A. Ainsworth. CFTR mediates cAMP Ca²⁺-activated duodenal epithelial HCO₃⁻ secretion. *Am J Physiol* 1997;272:G872-G878
17. D.L. Hogan, D.L. Crombie, J. I. Isenberg, P.Svendsen, O.B. Schaffalitzky de Muckadell, M. A. Ainsworth. Acid-stimulated duodenal bicarbonate secretion involves a CFTR-mediated transport pathway in mice. *Gastroenterology* 1997;113:533-541.
18. M. A. Ainsworth, D.L. Hogan, R. C. Rapiet, M. Amelsberg, A. D. Dreilinger, J. I. Isenberg. Acid/base transporters in human duodenal enterocytes. *Scand J Gastroenterol* 1998;33:1039-46.
19. O. H. Nielsen, P. Gionchetti, M. A. Ainsworth, B. Vainer, M. Campieri, N. Borregaard, L. Kjeldsen. Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8 and tumor necrosis factor- α in ulcerative colitis. *Am J Gastroent* 1999;94:2923-8.
20. J. Praetorius, D. Andreasen, B. L. Jensen, M. A. Ainsworth, U. G. Friis, T. Johansen. NHE1, NHE2 and NHE3 contribute to regulation of intracellular pH in murine duodenal epithelial cells. *Am J. Physiol. Gastrointest. Liver Physiol.* 2000;278:G197-G206.
21. J. Praetorius, H. Hager, S. Nielsen, C. Aalkjaer, U. G. Friis, M. A. Ainsworth, T. Johansen. Molecular and functional evidence for electrogenic and electroneutral Na⁽⁺⁾-HCO₃⁽⁻⁾ cotransporters in murine duodenum. *Am J Physiol Gastrointest Liver Physiol.* 2001 Mar;280:G332-43.
22. J. Praetorius, U. G. Friis, M. A. Ainsworth, O. B. Schaffalitzky de Muckadell, T. Johansen. The cystic fibrosis transmembrane conductance regulator is not a base transporter in isolated duodenal epithelial cells. *Acta Physiol Scand.* 2002 Apr;174:327-36.
23. H. Glad H, M. A. Ainsworth, P. Svendsen, J. Fahrenkrug, O. B. Schaffalitzky De Muckadell. Effect of vasoactive intestinal Peptide and pituitary adenylate cyclase-activating polypeptide on pancreatic, hepatic and duodenal mucosal bicarbonate secretion in the pig. *Digestion.* 2003;67:56-66.
24. M. A. Ainsworth, K. Bendtzen, J. Brynskov. Tumour necrosis factor- α binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. *Am J Gastroenterol* 2008;103(4):944-8.
25. A. S. Teisner, M. A. Ainsworth, J. Brynskov. Long-term effects and colectomy rates in ulcerative colitis patients treated with infliximab: a Danish single center experience. *Scand J Gastroenterol.* 2010; 45: 1457-63.
26. C. Steenholdt, K. Bendtzen, J. Brynskov, O. Østergaard Thomsen, M. A. Ainsworth. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. *Scand J Gastroenterol.* 2011; 46: 310-8.
27. C. Steenholdt, M. Svenson, K. Bendtzen, O. Østergaard Thomsen, J. Brynskov, M. A. Ainsworth. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. *Aliment Pharmacol Ther* 2011; 34: 51-8.
28. C. Lallemand C, N. Kavrochorianou, C. Steenholdt, K. Bendtzen, M. A. Ainsworth, J. F. Meritet, B. Blanchard, P. Lebon P. Taylor, P. Charles, S. Alzabin, M. G. Tovey. Reporter Gene Assay for the

- Quantification of the Activity and Neutralizing Antibody Response to TNF α Antagonists. *J Immunol Methods*. 2011;373(1-2):229-39.
29. C. Steenholdt, C. Enevold, M. A. Ainsworth, J. Brynskov, O. Ø. Thomsen, K. Bendtzen. Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease. *Aliment Pharmacol Ther*. 2012;36(7):650-9.
30. C. Steenholdt, A. Molazahi, M. A. Ainsworth, J. Brynskov, O. Ø. Østergaard Thomsen, J. B. Seidelin. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study. *Scand J Gastroenterol*. 2012;47(5):518-27.
31. C. Steenholdt, M. Al-Khalaf, J. Brynskov, K. Bendtzen, O. Ø. Thomsen, M. A. Ainsworth. Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease. *Inflamm Bowel Dis*. 2012 Dec;18(12):2209-17.
32. C. Steenholdt, M.A. Ainsworth, M. Tovey, T.W. Klausen, O.Ø. Thomsen, J. Brynskov, K. Bendtzen. Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn's disease. *Ther Drug Monit*. 2013;35(4):530-8.
33. C. Steenholdt, J. Brynskov, O.O. Thomsen, L.K. Munck, J. Fallingborg, L.A. Christensen, G. Pedersen, J. Kjeldsen, B.A. Jacobsen, A.S. Oxholm, J. Kjellberg, K. Bendtzen, M. A. Ainsworth. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. *Gut*. 2014;63(6):919-27.
34. C. Steenholdt, K. Bendtzen, J. Brynskov, O.Ø. Thomsen, M. A. Ainsworth. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial. *Am J Gastroenterol*. 2014;109(7):1055-64.
35. M. T. Frederiksen, M. A. Ainsworth, J. Brynskov, O.Ø. Thomsen, K. Bendtzen, C. Steenholdt. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD. *Inflamm Bowel Dis*. 2014;20(10):1714-21.
36. C. Steenholdt, K. Bendtzen, J. Brynskov, O.Ø. Thomsen, L.K. Munck, L.A. Christensen, G. Pedersen, J. Kjeldsen, M. A. Ainsworth. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease. *J Crohns Colitis*. 2015 Mar;9(3):238-45. doi:10.1093/ecco-jcc/jjv004. Epub 2015 Jan 9.
37. M. H. Jeppesen, M. A. Ainsworth. Telephone reminders reduced the non-attendance rate in a gastroenterology outpatient clinic. *Dan Med J*. 2015 Jun;62(6). pii: A5083.
38. C. Steenholdt, M.T. Frederiksen, K. Bendtzen, M. A. Ainsworth, O.Ø. Thomsen, J. Brynskov. Time Course and Clinical Implications of Development of Antibodies Against Adalimumab in Patients With Inflammatory Bowel Disease. *J Clin Gastroenterol*. 2016 Jul;50(6):483-9.
39. C. Steenholdt, J. Brynskov, O.Ø. Thomsen, L.K. Munck, L.A. Christensen, G. Pedersen, J. Kjeldsen, M. A. Ainsworth. Implications of Infliximab Treatment Failure and Influence of Personalized Treatment on Patient-reported Health-related Quality of Life and Productivity Outcomes in Crohn's Disease. *J Crohns Colitis*. 2015 Nov;9(11):1032-42.
40. K.R. Christensen, C. Steenholdt, S.S. Buhl, M. A. Ainsworth, O.Ø. Thomsen, J. Brynskov. Systematic Information to Health-Care Professionals about Vaccination Guidelines Improves Adherence in Patients With Inflammatory Bowel Disease in Anti-TNF α Therapy. *Am J Gastroenterol*. 2015 Jun 2. doi: 10.1038/ajg.2015.162. [Epub ahead of print].
41. C. Steenholdt, J. Brynskov, O.Ø. Thomsen, L.K. Munck, J. Fallingborg, L.A. Christensen, G. Pedersen, J. Kjeldsen, B. A. Jacobsen, A. S. Oxholm, J. Kjellberg, K. Bendtzen, M. A. Ainsworth. Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn's Disease Patients Failing Infliximab. *Dig Dis Sci*. 2015 Sep;60(9):2762-70. doi: 10.1007/s10620-015-3581-4. Epub 2015.
42. C. Steenholdt, M. Coskun, S. Buhl, K. Bendtzen, M. A. Ainsworth, J. Brynskov, O. H. Nielsen. Circulating Cytokines and Cytokine Receptors in Infliximab Treatment Failure Due to TNF- α Independent Crohn Disease. *Medicine (Baltimore)*. 2016;Apr;95(16):e3417.
43. S. S. Buhl, C. Steenholdt, J. Brynskov, O. Ø. Thomsen, K. Bendtzen, M. A. Ainsworth. Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial. *BMJ Open*. 2014 Dec 18;4(12):e005887.
44. Edlund H, Steenholdt C, Ainsworth MA, Goebgen E, Brynskov J, Thomsen OØ, Huisinga W, Kloft

- C. Magnitude of Increased Infliximab Clearance Imposed by Anti-infliximab Antibodies in Crohn's Disease Is Determined by Their Concentration. *AAPS J.* 2017 Jan;19(1):223-233. doi: 10.1208/s12248-016-9989-8. Epub 2016 Oct 13. PubMed PMID: 27739011.
45. Buhl S, Steenholdt C, Rasmussen M, Borghede MK, Brynskov J, Thomsen OØ, Ainsworth MA. Outcomes After Primary Infliximab Treatment Failure in Inflammatory Bowel Disease. *Inflamm Bowel Dis.* 2017 Jul;23(7):1210-1217. doi: 10.1097/MIB.0000000000001117. PubMed PMID: 28445244.
46. Sørensen JØ, Nielsen OH, Andersson M, Ainsworth MA, Ytting H, B elard E, Jess T. Inflammatory bowel disease with primary sclerosing cholangitis: A Danish population-based cohort study 1977-2011. *Liver Int.* 2018 Mar;38(3):532-541. doi: 10.1111/liv.13548. Epub 2017 Sep 5.
47. Bjerrum JT, Steenholdt C, Ainsworth MA, Nielsen OH, Reed MA, Atkins K, G unther UL, Hao F, Wang Y. Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease. *BMC Med.* 2017 Oct 16;15(1):184. doi: 10.1186/s12916-017-0949-7. PubMed PMID: 29032767; PubMed Central PMCID: PMC5641999.
48. Mogensen DV, Brynskov J, Ainsworth MA, Nersting J, Schmiegelow K, Steenholdt C. A Role for Thiopurine Metabolites in the Synergism Between Thiopurines and Infliximab in Inflammatory Bowel Disease. *J Crohns Colitis.* 2018 Feb 28;12(3):298-305. doi: 10.1093/ecco-jcc/jjx149.
49. Holmstr m RB, Mogensen DV, Brynskov J, Ainsworth MA, Nersting J, Schmiegelow K, Steenholdt C. Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease. *Dig Dis Sci.* 2018 Jun;63(6):1583-1591. doi: 10.1007/s10620-018-5020-9. Epub 2018 Mar 21.
- Review articles
1. M. A. Ainsworth, J. Kjeldsen : Gastroduodenalmukosaens forsvarsmekanismer : mucus og bicarbonats betydning for udviklingen af peptisk ulcus. *Ugeskr L eager* 1989;151:270813.
 2. M. A. Ainsworth, J. Kjeldsen: Gastroduodenalmukosaens forsvarsmekanismer: betydningen af epitheliale og subepitheliale faktorer for udviklingen af akutte og kroniske ulcerationer. *Ugeskr L eager* 1990;152:2542-46.
 3. D.L. Hogan, M. A. Ainsworth, J.I. Isenberg. Gastroduodenal Bicarbonate secretion. *Alim Pharm Ther* 1994;8:475-488.
 4. M. A. Ainsworth, J. Ersboll. [Summary of product characteristics--what is it and how is it used?] *Ugeskr L eager.* 1999 Oct 4;161:5565.
 5. M. A. Ainsworth. [New drugs and European procedures of approval. The European Agency for the Evaluation of Medicinal Products' role] *Ugeskr L eager.* 2003 Apr 14;165:1648-9.
 6. O. H. Nielsen, M. A. Ainsworth, I. Ahnfelt-R onne. [Physicians' participation in clinical drug trials] *Ugeskr L eager.* 2003 Apr 14;165:1639.
 7. M. A. Ainsworth, J. Ersb ll. L egemiddelregistrering. *M nedsskrift for Praktisk L egegerning* 2004;5:637-44.
 8. M. A. Ainsworth, O. H. Nielsen. [Pharmacogenetics--new therapeutic possibilities]. *Ugeskr L eager.* 2005;167:2141.
 9. M. A. Ainsworth, O. H. Nielsen. [Transjugular intrahepatic portosystemic stent-shunts or paracentesis in the treatment of cirrhotic patients with refractory ascites]. *Ugeskr L eager.* 2005;167:3273-6.
 10. O. H. Nielsen, M. A. Ainsworth, C. Csillag, J. Rask-Madsen. Systematic review: coxibs, non-steroidal anti-inflammatory drugs or no cyclooxygenase inhibitors in gastroenterological high-risk patients? *Aliment Pharmacol Ther.* 2006 Jan;23:27-33.
 11. M. A. Ainsworth, J. Brynskov. Anti-TNF-  behandling af patienter med aktiv colitis ulcerosa. *Ugeskr L eager* 2007;169:789-91.
 12. Munck L.K., Ainsworth M. A. Tegaserod in treatment of women with irritable bowel syndrome. *Ugeskr L eager.* 2007;169:2190-2.
 13. K. Bendtzen, M. A. Ainsworth, C. Steenholdt, O.  stergaard Thomsen, J. Brynskov. Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. *Scan J Gastroenterol.* 2009; 44(7):774 – 781
 14. C. Steenholdt, M. A. Ainsworth, O.  stergaard Thomsen, J. Brynskov, K. Bendtzen. [Monitoring of bioavailability, pharmacokinetics and immunogenicity of tumour necrosis factor-alpha inhibitors].

Ugeskr Laeger. 2010; 172: 44-7.

15. O.H. Nielsen, J.T. Bjerrum, J.B. Seidelin, C. Nyberg, M. A. Ainsworth. Biological treatment of Crohn's disease. *Dig Dis*. 2012;30 Suppl 3:121-33.

16. O.H. Nielsen, M. A. Ainsworth. Tumor necrosis factor inhibitors for inflammatory bowel disease. *N Engl J Med*. 2013;369(8):754-62.

17. O.H. Nielsen, M. A. Ainsworth, M. Coskun, G. Weiss G. Management of Iron-Deficiency Anemia in Inflammatory Bowel Disease: A Systematic Review. *Medicine (Baltimore)*. 2015 Jun;94(23):e963.

18. O. H. Nielsen, J. B. Seidelin, M. A. Ainsworth, M. Coskun. Will novel oral formulations change the management of inflammatory bowel disease? *Expert Opin Investig Drugs*. 2016 Jun;25(6):709-18.

19. Steenholdt C, Bendtzen K, Brynskov J, Ainsworth MA. Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies. *Inflamm Bowel Dis*. 2016 Aug;22(8):1999-2015. doi: 10.1097/MIB.0000000000000772. PubMed PMID: 27135483.

20. Bendtzen K, Steenholdt C, Brynskov J, Thomsen OØ, Ainsworth MA. Monitoring immunogenicity of protein-based TNF antagonists. *Frontline Gastroenterol*. 2016 Apr;7(2):152-154. doi: 10.1136/figastro-2015-100596. Epub 2015 May 14. PubMed PMID: 28839850; PubMed Central PMCID: PMC5369473.

Commentary/letter to the editor/editorials

1. M. A. Ainsworth. Exogenous prostaglandins, alkaline secretion and protection of duodenal mucosa. *Dig Dis Sci*. 1990;35:918-9.

2. K. Bendtzen, C. Steenholdt, M. A. Ainsworth, O. Østergaard Thomsen, J. Brynskov. Comment on 'Predicting the response to infliximab from trough serum levels'. *Gut*. 2010; 59: 1298-9.

3. C. Steenholdt C, M. Svenson, K. Bendtzen K, O.Ø. Thomsen, J. Brynskov, M. A. Ainsworth. Incidence of acute severe infusion reactions to infliximab depends on definition used rather than assay: authors' reply. *Aliment Pharmacol Ther* 2011;34:404-405.

4. O. H. Nielsen, M. A. Ainsworth. Which biologic agent is best for ulcerative colitis. *Ann Intern Med*. 2014;160(10):733-4.

5. M. A. Ainsworth. Enterocoating af acetylsalicylsyre - betyder det noget? *Ugeskr Laeger*. 2014 Apr 28;176(9). pii: V65829.

6. C. Steenholdt, M. A. Ainsworth. Authors' response: Importance of defining loss of response before therapeutic drug monitoring. *Gut*. 2015 Aug;64(8):1340-1. doi:10.1136/gutjnl-2014-309044. Epub 2015 Jan 14. PubMed PMID: 25588404.

Case reports

1. M. Hauser, M. A. Ainsworth, H. Dietzel : Eosinophil gastroenterit med ascites og leverinvolvering. *Ugeskr Læger* 1988;150:14779.

2. C. Steenholdt C, M. Al-Khalaf, M. A. Ainsworth, J. Brynskov. Therapeutic infliximab drug level in a child born to a woman with ulcerative colitis treated until gestation week 31. *J Crohns Colitis*. 2012;6(3):358-61.

3. C. Steenholdt, M. Svenson, K. Bendtzen, O. Ø. Thomsen, J. Brynskov, M. A. Ainsworth. Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease. *J Crohns Colitis*. 2012;6(1):108-11.

Book chapters

1. M. A. Ainsworth. Is extrapolation of safety and efficacy data possible. In G. Rogler, H. Herfarth, T. Hibi and O.H. Nielsen. *Anti-tumor necrosis factor therapy in inflammatory bowel disease. Frontiers of Gastrointestinal Research, Vol 34. Karger. Basel 2015.*

Dissertations

1. M. A. Ainsworth. Duodenal mucosal bicarbonate secretion and its importance to mucosal protection and neutralization of acid in the duodenum (ph.d.-afhandling). Odense Universitet 1992.

2. M. A. Ainsworth. Duodenal mucosal bicarbonate secretion: secretion mechanisms, physiology and pathophysiological importance (doktordisputats). Odense Universitet 2000.

Projects

Ongoing Scientific research Projects (in collaboration with researcher in Denmark, Norway, Sweden and Finland)

Usefulness of measurement of through leves and anti-drug antibodies in selection of treatment in patients with Crohn's disease with secondary failure to infliximab treatment

Can infliximab be safely discontinued in patients with Crohn's disease who have long term sustained

responsen ro infliximab

Clinical benefit of treat to target strategy in IBD

Memberships

Danish Medical Association (DADL)

Danish Society of Internal Medicine (DSIM)

Danish Society of Hepatology and Gastroenterology (DSGH)

European Crohn's and Colitis Organisation (ECCO)

American Gastroenterological Association (AGA)

Other Relevant Information

Served as part time assessor for the Danish Medicines Agency for several years

Vice-chairman for the Danish Medicines Evaluation Board ("Registreringsnævnet" later "Lægemiddelnævnet") from 2009 until 2018